Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024

CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, announced today that it will be presenting preclinical data on its lead program IMM-1-104 at the American Association for Cancer Research (AACR) annual meeting, held April 5-10 in San Diego, California. Details for the poster presentation are as follows: Title: Activity of IMM-1-104 alone or in combination with chemotherapy in RAS-altered pancreatic cancer modelsDate and Time: Tuesday Apr 9, 2024, 9:00 AM – 12:30 PM PTPoster Session: In Vivo Imaging and Humanized ModelsLocation: Poster Section 9, Poster Board #19Abstract Number: 4195 The abstract is available on the AACR Online Program and will be published in the online Proceedings of the AACR. Following presentation, the poster will be available on the publications section of Immuneering’s website. About Immuneering Corporation Immuneering is a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The Company aims to achieve universal activity through deep cyclic inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering’s lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor currently in a Phase 1/2a study in patients with advanced solid tumors harboring RAS mutations. IMM-6-415 is an oral, twice-daily deep cyclic inhibitor and will be evaluated in a Phase 1/2a study in patients with advanced solid tumors harboring RAS or RAF mutations. The company’s development pipeline also includes several early-stage programs. For more information, please visit www.immuneering.com. Media Contact:Gina NugentNugent [email protected] Investor Contacts:Laurence WattsGilmartin [email protected] or Kiki Patel, PharmDGilmartin [email protected]